180 Life Sciences Corp. is a biotechnology firm currently in the clinical trial phase, dedicated to pioneering novel pharmaceutical treatments that address significant unmet medical needs in areas such as inflammatory conditions, fibrotic disorders, and pain management. This research and development effort is powered by the collective expertise of distinguished therapeutics specialists from Oxford University, the Hebrew University, and Stanford University. The company was co-founded by Marc Feldmann, Lawrence J.